ProteoNic's 2G UNic Technology Licensed by Ginkgo Bioworks for $22.2M BARDA-Funded Anti-Filovirus Antibody Manufacturing Project
核心洞察
ProteoNic BV (搜索) has licensed its proprietary 2G UNic (搜索)® vector and transposon technology to Ginkgo Bioworks for a $22.2 million BARDA (搜索)-funded project aimed at developing cost-effective monoclonal antibody manufacturing for anti-filovirus therapies.
The project brings together a consortium including Advanced BioScience Laboratories (搜索), Isolere Bio (搜索), NeuImmune (搜索), and ProteoNic to create rapid, scalable biomanufacturing solutions for critical medical countermeasures against Ebola (搜索) and Sudan Virus (搜索) infections.
ProteoNic's 2G UNic (搜索) technology is designed to maximize expression and productivity in mammalian systems, potentially enhancing manufacturing efficiency and yield while reducing time and costs for large-scale bioproduction.
ProteoNic BV (搜索) announced that Ginkgo Bioworks has licensed its proprietary 2G UNic (搜索)® technology for a $22.2 million project funded by the Biomedical Advanced Research and Development Authority (BARDA (搜索)) to advance monoclonal antibody manufacturing for anti-filovirus therapies. The project, awarded through BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), aims to develop innovations that strengthen and reduce costs of domestic biomanufacturing of monoclonal antibodies (搜索) to treat infections by filoviruses (搜索), including Ebola (搜索) (EBOV) and Sudan Virus (搜索) (SUDV).
Multi-Company Consortium Approach
The project brings together a comprehensive team led by Ginkgo Bioworks that includes Advanced BioScience Laboratories (搜索) (ABL), Isolere Bio (搜索) by Donaldson, NeuImmune (搜索), and ProteoNic. The consortium will develop and integrate innovative technologies spanning the full monoclonal antibody production process, from cell line development through purification, to create a more rapid, scalable, and cost-effective biomanufacturing solution for critical medical countermeasures.
ProteoNic's Technology Contribution
ProteoNic's contribution focuses on the application of its proprietary 2G UNic (搜索) vector and transposon technologies, which are designed to maximize expression and productivity in mammalian systems. By integrating these tools into the monoclonal antibody production platform, ProteoNic aims to significantly enhance manufacturing efficiency and yield, reducing both time and cost for large-scale bioproduction.
"We are proud that Ginkgo has chosen to license and apply our 2G UNic (搜索) in this important initiative," said Frank Pieper, CEO of ProteoNic. "Our 2G UNic technology has consistently demonstrated substantial improvements in protein expression and manufacturing productivity. Contributing this capability to a project of such public health importance aligns perfectly with our mission to enable more efficient, accessible biologics production globally."
Strategic Implications for Biomanufacturing
This collaboration underscores ProteoNic's continued expansion into next-generation biologics manufacturing, supporting applications in both therapeutic protein production and cell and gene therapy. By enabling higher productivity from existing manufacturing infrastructure, ProteoNic's technology provides a sustainable path to strengthening biomanufacturing resilience in response to future global health threats.
The project has been awarded through the BioMaP-Consortium, overseen by BARDA (搜索) and managed by Advanced Technology International (ATI), and funded with federal funds from the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), and BARDA under Other Transaction number #75A50123D00003.